ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 578,57
-0,71%
Dow Jones
40 211,72
0,53%
DAX
18 497,92
-0,55%
Brent Oil
83,765
-0,68%
Bitcoin
63 180,20
-2,58%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
18/09/201714h07Business WireTeva Announces Sale of Remaining Assets in Specialty Global Women’s Health Portfolio for $1.38 BillionNYSE:TEVATeva Pharmaceutical Industries Ltd
15/09/201715h00PR Newswire (US)FinancialInsiders.com Earnings Recap Week Ending September 15th, 2017NYSE:TEVATeva Pharmaceutical Industries Ltd
15/09/201709h46Dow Jones NewsIndivior Files New Lawsuits for Alleged Patent InfringementNYSE:TEVATeva Pharmaceutical Industries Ltd
14/09/201714h10Edgar (US Regulatory)Report of Foreign Issuer (6-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/09/201714h00Business WireTeva to Present Data for AUSTEDO® (deutetrabenazine) Tablets and Other Research at the 2017 Psych CongressNYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201723h15Dow Jones NewsADRs End Mostly Higher; JD Trades ActivelyNYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201714h00Business WireTeva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Ri...NYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201710h00PR Newswire (US)Teva Presents First Real-World Evidence Demonstrating Treatment with DuoResp Spiromax® Inhaler was Comparable to Symbicort T...NYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201709h03Dow Jones NewsOpioid Makers Challenge Suit -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201709h02Dow Jones NewsTeva Fills CEO Spot After Long Search -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201701h14Dow Jones NewsOpioid Painkiller Makers Seek to Dismiss State LawsuitNYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/201700h08Dow Jones NewsADRs End Higher; Teva Trades ActivelyNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201723h33Dow Jones NewsTeva Pharmaceutical to Sell Paragard Rights to Medical-Device Firm Cooper For $1.1 BillionNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201722h15GlobeNewswire Inc.The Cooper Companies Announces Definitive Agreement to Acquire PARAGARD® IUD From TevaNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201722h15Business WireTeva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgicalNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201720h25Dow Jones NewsTeva Finally Appoints New Chief Executive After Months of Speculation -- 4th UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201714h42Dow Jones NewsTeva Finally Appoints New Chief Executive After Months of Speculation -- 3rd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201712h46Dow Jones NewsTeva Names Kare Schultz as New Chief Executive -- 2nd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201710h03Dow Jones NewsTeva Names Kare Schultz as New Chief Executive -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/201708h04Business WireTeva Names Kåre Schultz as President and Chief Executive OfficerNYSE:TEVATeva Pharmaceutical Industries Ltd
09/09/201714h00Business WireTeva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic & Epis...NYSE:TEVATeva Pharmaceutical Industries Ltd
09/09/201709h02Dow Jones NewsPatents Take Refuge With Indian Tribe -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/201722h59Dow Jones NewsAllergan Partners With Indian Tribe to Protect Drug Patents -- 3rd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/201721h49Dow Jones NewsAllergan Partners With Indian Tribe to Protect Drug Patents -- 2nd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/201721h31Dow Jones NewsAllergan Partners With Indian Tribe to Protect Drug Patents -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/201720h07Dow Jones NewsAllergan Partners With Indian Tribe to Protect Drug PatentsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/201701h10Dow Jones NewsNew Mexico Sues Drugmakers, Distributors Over Opioid CrisisNYSE:TEVATeva Pharmaceutical Industries Ltd
07/09/201723h13Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NYSE:TEVATeva Pharmaceutical Industries Ltd
06/09/201714h00Business WireTeva To Present New Asthma and COPD Data at the 2017 European Respiratory Society (ERS) International CongressNYSE:TEVATeva Pharmaceutical Industries Ltd
05/09/201714h00Business WireTeva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache SocietyNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
VIV
Vivendi
NYSE
NKE
Nike
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
EU
AI
Air Liquide
EU
ORA
Orange
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
NASDAQ
NVDA
NVIDIA
EU
RNO
Renault
EU
CAP
Capgemini
NYSE
MCD
McDonalds
EU
EN
Bouygues
EU
LR
Legrand
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés